Abcam Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Abcam şirketinin toplam hissedar öz sermayesi £719.2M ve toplam borcu £117.7M olup, bu da borç-öz sermaye oranını 16.4% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla £1.0B ve £307.9M dir. Abcam 'in FAVÖK'ü £73.0M faiz karşılama oranı 9 dur. Şirketin £79.0M tutarında nakit ve kısa vadeli yatırımları bulunmaktadır.

Anahtar bilgiler

16.4%

Borç/özkaynak oranı

UK£117.70m

Borç

Faiz karşılama oranı	9x
Nakit	UK£79.00m
Eşitlik	UK£719.20m
Toplam yükümlülükler	UK£307.90m
Toplam varlıklar	UK£1.03b

Son finansal sağlık güncellemeleri

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: ABCM 'nin kısa vadeli varlıkları ( £255.8M ) kısa vadeli yükümlülüklerini ( £188.9M ) aşıyor.

Uzun Vadeli Yükümlülükler: ABCM şirketinin kısa vadeli varlıkları ( £255.8M ) uzun vadeli yükümlülüklerini ( £119.0M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: ABCM 'nin net borç/öz sermaye oranı ( 5.4% ) tatmin edici olarak değerlendirilmektedir.

Borcun Azaltılması: ABCM şirketinin borç/öz sermaye oranı son 5 yılda 0% seviyesinden 16.4% seviyesine yükseldi.

Borç Kapsamı: ABCM 'nin borcu işletme nakit akışı ( 22.3% ) tarafından iyi bir şekilde karşılanmaktadır.

Faiz Kapsamı: ABCM 'in borcuna ilişkin faiz ödemeleri EBIT ( 9 x kapsam) tarafından iyi bir şekilde karşılanmaktadır.

Abcam Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Abcam Files Form 15

Abcam Provides Update on AIM Delisting

Abcam plc Announces Proposed Cancellation of AIM Shares

Abcam Board Decides to Pursue A Proposal to Cancel the Admission of the Shares to Trading on Aim

Recent updates

Abcam Files Form 15

Abcam plc(NasdaqGS:ABCM) dropped from NASDAQ Composite Index

Jonathan Milner Issues Statement Responding to the Glass Lewis Report

Jonathan Milner Continues Opposition to Danaher Corporation Acquisition

Jonathan Milner Releases Presentation to Abcam plc Shareholders

Jonathan Milner issues Open Letter to shareholders of Abcam plc

Jonathan Milner issues Open Letter to Shareholders of Abcam plc

Jonathan Milner Opposes Danaher's Acquisition of Abcam

Abcam plc Suspends Financial Guidance for the Fiscal 2023 and Fiscal 2024

Abcam plc Suspends Financial Guidance for the Fiscal 2023 and Fiscal 2024

Danaher Corporation (NYSE:DHR) entered into definitive agreement to acquire Abcam plc (NasdaqGS:ABCM) for $5.7 billion.

Jonathan Milner Sends an Open Letter to Abcam plc

Abcam plc Provides Revenue Guidance for the First Half Ending June 30, 2023

Jonathan Milner Announces Suspension of Proxy Solicitation

Abcam plc Provides Revenue Guidance for Fy2023 and Fy2024

Jonathan Milner Issues an Open Letter to shareholders of Abcam plc

Jonathan Milner Sends a Letter to Abcam plc

Jonathan Milner issues Open Letter to shareholders of Abcam plc

Jonathan Milner Calls Extraordinary General Meeting to Replace Directors at Abcam

Abcam plc Reiterates Earnings Guidance for the Years 2023 and 2024

Abcam plc to Report Fiscal Year 2022 Results on Mar 20, 2023

Abcam Provides Update on AIM Delisting

Abcam plc Announces Proposed Cancellation of AIM Shares

Abcam: A Good Growth Stock In The Healthcare Market

Abcam plc Provides Revenue Guidance for the Full Year Ending December 31, 2022

Abcam plc Appoints Luba Greenwood as Non-Executive Director

Abcam ADS Non-GAAP EPS of 14.00p, revenue of £185.2M

Abcam Board Decides to Pursue A Proposal to Cancel the Admission of the Shares to Trading on Aim

Abcam plc to Report First Half, 2022 Results on Sep 12, 2022

Abcam plc, Annual General Meeting, May 18, 2022

Abcam plc to Report 18 Months Period Ending Dec 31, 2021 Results on Mar 14, 2022

Abcam plc Provides Group Revenue Guidance for the Twelve Months Ended 31 December 2021

Abcam plc Provides Revenue Guidance for the Six-Months to 31 December 2021 and Year Ending December 31, 2024

Abcam plc (AIM:ABC) entered into a definitive agreement to acquire BioVision, Inc. from Boai NKY Medical Holdings Ltd. (SZSE:300109) for approximately $340 million.

Abcam: A Promising Business Model In The Drug Industry

Abingdon Health Signs Collaboration and Co-Marketing Agreement with Abcam

Abcam plc Appoints Non-Executive Directors

Abcam rallies on 1H trading update

Abcam plc to Report Q2, 2021 Results on Mar 08, 2021

Abcam plc, Annual General Meeting, Dec 04, 2020

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Sağlıklı şirketleri keşfedin